Cutia Therapeutics (HK:2487) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Cutia Therapeutics has presented positive results from their Phase III clinical trial of CU-10201, a new topical acne treatment, at the 13th Asian Dermatology Congress. The treatment showed significant improvement in patients with moderate to severe acne over 12 weeks, with no serious adverse events reported. CU-10201 has received priority review designation and an accepted New Drug Application in the PRC, signaling a potential breakthrough in acne therapy.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.